Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plavix and Aspirin in Metastatic Breast Cancer
NCT00263211Phase 2Terminated
- Sponsor
- Washington University School of Medicine
- Start
- Jan 2006
- Primary completion
- Sep 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in breast cancer comparing Plavix and Aspirin with Observation (2 arms). Primary endpoints: Platelet Inhibition of Circulating Tumor Cells (CTCs) Measured by the Number of Patients With Detectable CTCs at 4 weeks and Safety and Tolerability of Aspirin and Plavix Measured by the Number of Patients Who Discontinue the Study Drug at 6 months. Started Jan 2006; status: terminated.
02
Drugs
clopidogrel
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00263211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00263211.